Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Source: Vision and Value  (2/8/22)
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19. More >

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Source: Streetwise Reports  (2/7/22)
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal. More >

Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Source: Streetwise Reports  (2/3/22)
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke. More >

Co. Focused on Pipeline of Drug Candidates
  (1/31/22)
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report. More >

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes
Source: Streetwise Reports  (1/31/22)
Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals. More >

Neuroscientist With Research Program Joins Biotech's SAB
Source: Streetwise Reports  (1/29/22)
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program. More >

Pharma to Test if DMT Helps Brain Regain Function Post Stroke
Source: Streetwise Reports  (1/28/22)
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman. More >

Co. Meets Goals in COVID Drug Trial
Source: Streetwise Reports  (1/28/22)
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data. More >

Possible Treatment for CRC Shows Promise
  (1/25/22)
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report. More >

Bone Cancer Drug Meets Goals, Stocks Rise
Source: Streetwise Reports  (1/25/22)
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size. More >

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen
  (1/24/22)
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report. More >

Fourth COVID-19 Vaccine Shot Shown Less Effective
  (1/24/22)
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report. More >

‘Strong Data’ Expected From Todos Medical Data Lock
Source: Vision and Value  (1/24/22)
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir. More >

First NSCLC Patient Dosed With Trial Therapeutic
  (1/22/22)
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report. More >

Fund Triples Holding of Drug Repurposing Firm
Source: Streetwise Reports  (1/20/22)
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report. More >

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
Source: Streetwise Reports  (1/19/22)
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met. More >

Derm Biopharma Named Top Growth Pick For 2022
  (1/18/22)
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report. More >

This Pharmaceutical Company Has a Brilliant Concept
Source: Penny Queen  (1/17/22)
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company. More >

Ph1 Trial Results of Dementia Drug Positive
  (1/12/22)
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report. More >

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Source: Streetwise Reports  (1/12/22)
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study. More >

Biotech Co. Partners With Life Sciences Firms
  (1/11/22)
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. More >

2022 to Be Catalyst Rich for Biopharma
  (1/10/22)
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report. More >

Enrollment Done for COVID-19 Drug Trial
  (1/10/22)
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report. More >

Co.'s samRNA Vaccines Protect Better Against COVID Variants
  (1/7/22)
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. More >

AI Driven Drug Firm Partners With Merck
Source: Streetwise Reports  (1/7/22)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creationâ„¢ platform and Bionic Proteinâ„¢ technologies. More >